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GM-CSF secretion in cultures of normal and cancerous human renal
cells. Rates of secretion of granulocyte-macrophage colony stimulating
factor (GM-CSF) were measured in 50 primary cell cultures derived from
cancerous and normal human kidneys. Mean rates of GM-CSF secretion
measured by TF-1 cell proliferation assay (N = 21) and by ELISA (N =
31) were 2.5 and 7.8 ng/10° cells/24 hr, respectively. There was no
significant difference between the mean rates of GM-CSF secretion by
cancerous and normal renal cells. GM-CSF was also secreted by primary
renal cell cultures grown in serum-free medium and by renal cell lines.
GM-CSF mRNA was detected by RT-PCR in cultured renal cells, but not
in undissociated kidney tissue. Rates of GM-CSF secretion were reduced
up to 99% under conditions where the cellular density or substratum more
closely resembled the in vivo environment. Some cultured human renal
carcinoma cells (RCC) secreted GM-CSF at levels that occasionally
overlapped the levels produced by the GM-CSF gene-modified human
RCC vaccine now in phase I trial. The data indicate that GM-CSF is not
expressed in vivo, and that stable GM-CSF secretion is induced by the
dissociation and culture of human renal cells.
Several ongoing phase I trials of anticancer vaccines are based
on the premise that tumor cells genetically modified to secrete any
of several different cytokines can induce systemic, protective
immunity specific to the tumor cells [reviewed in 1]. Despite the
promising nature of these observations, there are several practical
drawbacks associated with the production of these vaccines. These
include the inability of retroviral vectors to transduce non-dividing
cells, the difficulty in obtaining sufficient numbers of transduced
cells (for example, when the transduction efficiency is low), the
potential change in the antigenic repertoire when substantial
expansion of the transduced culture is required, and the high cost
of producing pharmaceutical grade retroviral vectors that arc free
of replication-competent retrovirus. Therefore, alternate ap-
proaches for producing cytokine-secreting tumor cell vaccines
warrant further study.
In this context, primary cultures of some non-transduced cells
secrete cytokines spontaneously. For example, the induction of
IL-f3 and TNF-cs expression in dissociated, cultured human glial
cells has been recently described [2]. Also, primary cultures of
human renal carcinoma cells spontaneously secrete GM-CSF [3].
Moreover, we have determined that the rate of spontaneous
GM-CSF secretion in renal cell cultures occasionally equals the 24
to 48 ng GM-CSF/106 cells/24 hr produced by the GM-CSF-gene
modified renal cell carcinoma (RCC) vaccine presently in a phase
I trial [3—5]. This suggests that it might be possible to produce
vaccines directly from optimized primary cultures of renal cancer
cells without exogenous gene transfer. In the present study, the
feasibility of this strategy was evaluated by measuring the rates of
GM-CSF secretion in a total of 50 primary cultures derived from
both cancerous and adjacent, normal human kidney tissues. The
feasibility of optimizing the rate of GM-CSF secretion by manip-
ulating culture conditions, including seeding density and type of
cellular substratum, was also investigated.
It is not known if normal or cancerous human renal cells in vivo
produce GM-CSF in amounts similar to those produced in
primary culture. Therefore, GM-CSF mRNA levels were also
measured in undissociated kidney and compared to levels in
primary renal cell cultures producing defined amounts of GM-
CSF. Our results indicate for the first time that stable GM-CSF
expression is induced when normal or cancerous kidney tissue is
dissociated and cultured in vitro, and that the rate of GM-CSF
secretion is strongly influenced by the cellular environment in
these cultures.
Methods
Sources of renal tissues
Cancerous and adjacent, normal renal tissue was obtained from
the University of New Mexico Cancer Research and Treatment
Center Solid Tumor Facility and the Cooperative Human Tissue
Network. Tissue samples from the latter were shipped in RPMI-c
(RPMI 1640 medium supplemented with 10% heat-inactivated
fetal bovine serum, 2 mtvi L-glutamine, 100 U/mI penicillin and
100 .rg/ml streptomycin) at 4°C and either frozen or placed in
culture within 24 hours of excision.
Cell lines
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Two human cell lines were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA): A498 (ATCC
HTB 44), an epithelial-like line consistent with primary renal cell
carcinoma, and ACHN (ATCC 1611), initiated from a patient
with widely metastatic renal adenocarcinoma. An early passage
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fibroblast culture derived from human foreskin, HSF6, was pro-
vided by Dr. David Chen (Los Alamos National Laboratory). The
three lines were propagated in Eagle's minimal essential medium
with Earle's balanced salt solution, supplemented with 10%
heat-inactivated fetal bovine serum, non-essential amino acids, 2
mM L-glutamine, 100 U/mI penicillin and 100 .tg/mI streptomycin.
Primary cell culture
Tissue specimens were minced and incubated with type IV
collagenase at 37°C for two to four hours, after which the
dissociated cells were separated from large debris, washed in
RPMI-c and plated in standard 25 cm2 plastic tissue culture flasks
in RPMI-c. The cultures were incubated in a humid atmosphere
of 5% CO2 at 37°C. After 24 to 48 hours, depending on the extent
of attachment, unattached cells and other debris were removed
and fresh RPMI-c was added. After an additional 24 to 72 hours,
depending on the cell density and rate of proliferation, the cells
were detached from flasks with gentle trypsinization, counted, and
replated. Cultures were maintained over periods of two weeks to
two months at the desired cell densities. Lymphocytes, macro-
phages and red blood cells were also present in the tissue samples,
but they did not propagate under the described growth conditions.
The greater sensitivity of fibroblasts to dissociation by trypsin-
EDTA was exploited to remove contaminating fibroblasts from
the renal epithelial cell cultures. Briefly, maintenance medium
was removed, cells were rinsed with phosphate-buffered saline
and 0.25% trypsin-l mM EDTA (Life Technologies, Gaithersburg,
MD, USA) was added for one to five minutes at room tempera-
ture. Cells were monitored microscopically and when fibroblastic
cells became detached, serum-containing medium was added to
inhibit further dissociation. The dissociated fibroblasts were then
discarded and the culture medium was replenished. The purity of
representative tumor cell cultures was assessed with the RC 38
human monoclonal antibody (CalTag Laboratories, San Fran-
cisco, CA, USA). RC 38 is reported to stain approximately 95% of
primary RCC samples, as well as proximal tubule epithelial cells in
normal adult kidney sections [61. It does not stain carcinomas of
non-renal origin or sarcomas, including fibrosarcomas. Positive
staining ( 80% of cells per slide) was obtained in greater than
90% of samples of primary renal cell cultures. The human renal
cell line A498 and fibroblast cell line HSF6 were used as positive
and negative controls, respectively. Fetal bovine serum was free of
IL-2, IL-3, IL-7 and GM-CSF activities, as defined by cytokine
specific human cell proliferation assays, and free of proteins
cross-reactive with anti-IFN-a, TNF-a, TNF-p, G-CSF, GM-CSF,
IL-la, IL-2, IL-4, IL-6, lL-7 and IL-b human monoclonal and
polyclonal antibodies.
Collection of conditioned media
For TF-1 analyses, cells were plated at 0.5 to 1.0 X i0 cells/mI
in RPMI-c in standard 25 cm2 tissue culture flasks. Conditioned
media were removed 24 hours after plating and clarified first by
centrifugation at 10,000 >< g for 10 minutes at 4°C followed by
filtration through 0.2 tm pore, low protein-binding, non-pyro-
genic cellulose acetate membranes (Schleicher and Schuell,
Keene, NH, USA). Clarified supernatants were frozen and stored
at —70°C.
For ELISA analyses, cells were plated at 0.5 X io to 1.0 X 106
cells/ml in 25 cm2 flasks or six-well plates in either RPMI-c or
UltraCulture1 M a serum-free medium (BioWhittaker, Walkers-
ville, MD, USA). Standard tissue culture plastic flasks and, when
indicated, standard well plates (Becton Dickinson, Lincoln Park,
NJ, USA), Matrigel® culture inserts (with 0.2 M pore size
membranes; Collaborative Biomedical Products, Bedford, MA,
USA), and modified six-well plates were used. Matrigel® is a
basement membrane extract derived from Engelbreth-Holm-
Swarm (EHS) mouse tumor cells. It exhibits compositional,
structural and physical properties of basement membranes and
was used in an effort to more closely approximate the in vivo
environment. Its major constituents include laminin and collagen
IV. Modified six-well plates included ProNectin® F, a specialized
polymer containing the arg-gly-asp (R-G-D) sequence which is
crucial to function of fibronectin-specific cell surface receptors
such as those of the integrin family (Protein Polymer Technologies,
Inc., San Diego, CA, USA), Primaria®, a specialized polymer
containing polyamine-derived positive charges that are believed to
promote enhanced cellular attachment (Becton Dickinson, Lin-
coln Park, NJ, USA) and Biocoat® six-well plates coated with
defined proteins, including human fibronectin, mouse laminin,
mouse collagen IV, rat tail collagen type I, and poly-D-lysine
(Collaborative Biomedical Products, Bedford, MA, USA). Con-
ditioned media were removed 24 hours after plating, clarified by
centrifugation at 10,000 x g for 10 minutes at 4°C, and frozen and
stored at —20°C. Cells were enzymatically removed from repre-
sentative cultures according to the manufacturers' instructions
and counted.
TF-1 proliferation assay
The GM-CSF-dependent, erythroleukemic cell line, TF-1 [7],
was used to measure GM-CSF titers in the conditioned media
produced by 21 cultures of renal cells. Proliferation was measured
by the incorporation of 3H-thymidine. Concentrations of human
GM-CSF in the samples were calculated based on the incorpora-
tion produced by defined amounts of recombinant human GM-
CSF in control cultures. Polyclonal sheep anti-human GM-CSF
antibody (Immunex, Seattle, WA, USA) or pre-immune serum
was diluted 1:30 and added to TF-1 cells with the conditioned
media to confirm the specificity of the TF-1 cells' proliferative
response.
ELISA
GM-CSF and IL-ia titers were measured in 31 samples and 13
samples, respectively, of conditioned media using colorimetric
QuantikineTM Immunoassays (R&D Systems, Minneapolis, MN,
USA). Absorbance was measured at 450 am and corrected for
optical imperfections in the polystyrene microtiter plates by
subtracting the absorbance at 570 am. Concentrations of GM-
CSF and IL-la in the samples were calculated based on standard
curves generated with known amounts of recombinant human
GM-CSF and IL-la, ranging from 7.5 to 500 pg/mI and 3.9 to 250
pg/ml, respectively. According to the manufacturer's specifica-
tions, the minimal detectable levels of GM-CSF and IL-la using
these assays are 1.5 and 0.3 pg/mI, respectively. Only values falling
within the linear range of the standard curve were used in
calculating titers.
RT-PCR
PolyA+ RNA was isolated from snap-frozen renal tissue col-
lected at surgery using the FastTrackR and MicroFastTrackTM
systems, and reverse transcribed and amplified using the eDNA
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Table 1. TF-1 bioassay of GM-CSF secretion in primary human renal
cell cultures
Nanograms hGM-CSF/106 cells/24 hr
+anti-hGM-CSF +anti-GM-CSF
Patient Normal Ab Tumor Ab
1877 1.7 N.A. 2.5 N.A.
1790 0.4 NA. N.A. N.A.
1826 0.2 NA. 0.5 N.A.
1839 2.1 N.A. NA. N.A.
1840 5.1 0.2 2.3 0.2
1844 1.2 0.2 0.3 0.0
1851 0.3 0.0 4.5 0.1
1854 1.2 0.2 N.A. N.A.
1855 3.5 0.2 4.6 0.0
1865 10.4 0.0 0.3 0.0
1871 1.9 0.0 0.0 0.0
1874 4.2 0.0 4.1 0.0
Mean (SD) 2.7 (2.9) 0.1 (0.1) 2.1 (1.9) 0.0 (0.1)
Abbreviations are: Ab, anti-human GM-CSF antibody; N.A., not
sayed; SD, standard deviation of mean.
as-
Cycle1'M system, respectively (Invitrogen, San Diego, CA, USA).
First-strand synthesis was followed by a five minute denaturation
at 94°C and 35 cycles of cDNA amplification. Each cycle consisted
of denaturation at 94°C for one minute, annealing at 55°C for one
minute, and extension at 72°C for one minute. A final, five-minute
extension was performed at 72°C. Oligonucleotide primers were
synthesized by the University of New Mexico School of Medicine
Protein Chemistry Laboratory. PCR products and molecular
weight standards were resolved on 3% NuSieve 3:1 agarose gels
according to the manufacturer's instructions (FMC Corp., Rock-
land, ME, USA). One set of primers amplified a 104 bp element
spanning the junction of exons III-IV of human p-2 (h13-2)
microglobulin mRNA [8]. This primer set was used to demon-
strate the integrity and the approximate, relative concentrations of
the mRNA substrates. The second set of primers (sense NTs 38 to
60, 5'-CAC TGT GGC CTG CAG CAT CTC TG-3'; antisense
NTs 530 to 508, 5'-GTC CCT CCA AGA TGA CCA TCC TG-3')
was designed to amplify a 493 bp fragment spanning exons Ito IV
of the human GM-CSF mRNA. RT-PCR reactions run with MS-2
phage RNA in the presence and in the absence of MS-2 primers
served as positive and negative controls, respectively, for the
eDNA CycleTM system. To confirm that amplimers were eDNA
dependent (that is, that genomic DNA was not being amplified),
control reactions were formulated with RNA but without reverse
transcriptase. Under these conditions, no cDNA was anticipated
in the amplification mixtures. As a positive control for GM-CSF
cDNA amplification, reactions were formulated with plasmid
pCD-hGM (American Type Culture Collection), which contains
the human GM-CSF cDNA. In contrast, pCD-hGM DNA yielded
no product when hf3-2 microglobulin-specific primers were used in
place of GM-CSF-specific primers. The amplimers generated
from both sets of primers contained restriction enzyme cleavage
sites predicted from the corresponding mRNA sequences (data
not shown).
Results
GM-CSF secretion in primary cultures of human renal cells
The GM-CSF dependent, TF-1 cell proliferation assay was used
to measure the rates of secretion of biologically active GM-CSF
Table 2. ELISA assay of GM-CSF secretion in primary human renal
cell cultures
Patient
Nanograms hGM-CSF/106 cells/24 hr
Normal Tumor
1855 9.1 11.9
1883 7.8 18.3
1901 NA. 1.7
1920 11.3 2.0
1936 12.7 11.9
1947 3.7 NA.
1949 2.0 1.3
1955 5.6 11.4
1969 6.2 NA.
1975 6.3 1.0
1986 0.3 0.5
1996 0.6 5.3
1999 5.8 N.A.
2001 4.8 N.A.
2040 9.9 7.7
2044 3.2 13.5
2048 3.4 40.9
12998° 12.4 9.5
Mean (SD) 6.2 (3.9) 9.8 (10.6)
Abbreviations are: N.A., not assayed; SD, standard deviation of mean.
a Cells grown in serum-free medium
by primary cultures derived from 12 normal and 9 cancerous
samples of human kidney tissue. The rates of GM-CSF secretion
ranged from 0 to 10.4 ng/106 cells/24 hr (Table 1). There was no
statistically significant difference between the mean rates of
GM-CSF secretion by cultures derived from normal and cancer-
ous cells. Neither was there a significant correlation between
secretion and patient age (range 37 to 84 years), sex, or patho-
logical diagnosis (clear cell, oncocytic and papillary RCC, grades
II to IV). When anti-human GM-CSF antibody was added to the
conditioned media, the stimulation of TF-1 proliferation was
reduced by an average of 97%. In contrast, pre-immune serum
reduced proliferation by less than 4%, which is well within the
range of error inherent to this bioassay.
The rates of GM-CSF secretion were also measured by ELISA.
The rates of secretion by primary renal cultures derived from 17
normal and 14 cancerous samples ranged from 0.3 to 40.9 ng
GM-CSF/106 cells/24 hr (Table 2). The rates of GM-CSF secre-
tion in two samples grown in serum-free medium were 12.4 and
9.5 ng GM-CSF/106 cells/24 hr (Table 2). Again, there was no
statistically significant difference between the mean rates of
GM-CSF secretion by normal and cancerous cells (Table 2) or
between secretion and patient age, sex, or pathological diagnosis.
The rate of GM-CSF secretion was also independent of the
presence of penicillin and streptomycin in the medium, or the age
of the culture over the two months spanning the second to sixth
passages (data not shown).
The mean rate of GM-CSF secretion measured by ELISA was
3.2-fold higher than that measured by TF-J proliferation assay.
Two samples, 1855-normal and 1855-tumor, were measured by
both methods. In both instances, the rates determined by the
ELISA were 2.6-fold greater than those determined by TF-1
bioassay. It is therefore possible that only a portion of the
GM-CSF detected by the immunoassay employed was biologically
active, suggesting that secreted GM-CSF may not have been
completely stable during the 24-hour conditioning period.
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GM-CSF secretion in established human cell lines
ELISA also was used to measure GM-CSF secretion by two
human renal carcinoma cell lines, A498 and ACHN, and by HSF6,
an early passage human skin fibroblast line. The rates of GM-CSF
secretion were 1.1 and 1.4 ng/106 cells/24 hr, respectively, in
subconfluent A498 and ACHN. No GM-CSF activity was detected
in the conditioned medium from subconfluent HSF6, indicating
that secretion in this experiment, if any, was less than 0.05 ng/106
cells/24 hr.
GM-CSF secretion in non-renal tumors
In contrast to primary cultures derived from renal cells, there
was little or no GM-CSF secretion in primary cultures derived
from kidney tumors arising from non-renal cells. No GM-CSF
secretion was detected (by TF—1 assay) in a culture derived from
a colon carcinoma that had metastasized to the kidney, and the
rate of GM-CSF secretion in a primary culture derived from a
liposarcoma of the kidney was only 0.2 ng/106 cells/24 hr (by
ELISA). Similarly, the mean GM-CSF secretion in three primary
cultures derived from prostate tumors was 0.3 ng/106 cells/24 hr
(by ELISA).
IL-i a secretion in primary cultures of human renal cells
IL-la levels were measured in 11 randomly selected samples of
conditioned medium containing GM-CSF. The rates of IL-la
secretion were at background (0.0 to 0.02 ng/106 cells/24 hr) in 9
samples and 0.9 to 1.0 ng/106 cells/24 hr in 2 samples.
GM-CSF mRNA in human renal cells
PolyA+ RNA was first isolated from cultured primary renal
cells secreting 4.2 ng GM-CSF/106 cells/24 hr (by ELISA), con-
fluent A498 renal cells secreting 0.14 ng GM-CSF/106 cells/24 hr
(by ELISA) and transduced A498 cells secreting 100 ng GM-CSF/
106 cells/24 hr (by ELISA) from a human GM-CSF cDNA [9]
inserted into the IRES/HyTK vector [10, 11]. In each instance,
RT-PCR amplified a 493 base pair element spanning exons I-IV
of human GM-CSF mRNA (Fig. 1). This amplimer was not
detected after RT-PCR of polyA+ RNA isolated from any of four
normal and five cancerous specimens collected at surgery (Fig. 2).
In contrast, a 104 base pair element spanning exons III-IV of hf3-2
microglobulin mRNA was amplified from each of the polyA+
RNA preparations, showing that mRNA was intact and present at
roughly equivalent concentrations in each of the nine samples of
undissociated renal tissue (Fig. 2).
Effects of cell density on GM-CSF secretion
The rates of GM-CSF secretion were measured by ELISA in
four pairs of subconfluent and confluent primary renal cultures
(Fig. 3) and in subconfluent and confluent cultures of A498 and
ACHN. Cell densities in suspensions obtained from subconfluent
primary cultures ranged from 0.3 to 1 X io cells/ml, while those
from confluent primary cultures ranged from 1.8 to 6,7 x 106
cells/mi. The rates of secretion in subconfluent primary cultures
ranged from 7.6 to 11.5 ng/106 cells/24 hr, while those in confluent
cultures ranged from 0.1 to 1.6 ng/106 cells/24 hr. Secretion was
reduced in confluent primary cultures by an average of 88% (SD
9.0%). Similar results were obtained in A498 and ACHN (data
not shown).
Fig. 1. RT-PCR amplification of GM-CSFmRI"/A. Lane 1. HincII digest of
X-174 RF DNA; Lane 2. No RNA in reverse transcriptase (RT) reaction,
PCR with MS-2 primers (negative eDNA CycleTM system control); Lane
3. MS-2 RNA in RT reaction, PCR with MS-2 primers (positive eDNA
CycleTM system control); Lanes 4 to 7, PCR with GM-CSF primers
Templates: Lane 4. No eDNA (A498 mRNA, no RT); Lane 5. eDNA from
approximately 2 >< i05 A498 cells producing 0.14 ng GM-CSF/106 cells/24
hr; Lane 6. No eDNA ("1874-normal" mRNA, no RT); Lane 7. eDNA
from approximately 6 X i0 cultured renal cells from sample "1874-
normal" producing 4.2 ng GM-CSF/10' cells/24 hr (Table 2).
Effects of cell substratum on GM-CSF secretion
The rates of GM-CSF secretion were measured by ELISA in
replicates of subconfluent primary renal cultures grown on several
different substrata. The rate of GM-CSF secretion by primary
renal cells grown on Matrigel® was approximately 17% of the rate
by cells grown on standard plastic. Similar results were also
obtained with A498 and ACHN (data not shown). In contrast, the
rates of GM-CSF secretion by primary renal cells grown on all
other substrates were 70 to 106% of that measured in cells grown
on standard plastic (Fig. 4). Specifically, cells grown on mouse
laminin and mouse collagen IV secreted GM-CSF at 90% and
70%, respectively, of the rate by cells grown in standard plastic
culture wells.
Discussion
Four lines of evidence demonstrated that primary cultures of
human renal cells secrete GM-CSF. First, conditioned media
from these cultures stimulated the proliferation of TF-1, a GM-
CSF-dependent cell line. Second, the stimulation of TF-i cell
proliferation was blocked when anti-GM-CSF polyclonal antisera,
but not pre-immune serum, was added to the conditioned media.
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Fig. 4. Effcts of culture substrate on GM-CSF secretion in primary renal cell
cultures. Rates of GM-CSF secretion on (1) standard plastic; (2) Prima-
na® plastic; (3) Matrigel®; (4) human fibronectin; (5) ProNectinF®
plastic; (6) Poly-D-lysine; (7) rat collagen I; (8) mouse collagen IV; and (9)
mouse laminin substrates. Secretion rate is expressed as [ng/10*6].
( 495
Fig. 2. RT-PCR amplification of GM-CSF and hf3-2-microglobulin mRIVA.
Upper gel: PCR with hf3-2 microglobulin primers; Lower gel: PCR with
hGM-CSF primers. Templates: Lane 1. eDNA from transduced A498 cells
producing 100 ng GM-CSF/10 cells/24 hr; Lanes 2, 4, 8, 10. eDNA from
four undissociated normal kidney samples; Lanes 3, 5, 6, 7, 9. eDNA from
5 undissociated cancerous kidney samples; Lane 11. GM-CSF eDNA
(plasmid pCD-HGM); Lane 12. No DNA; Lane 13. HincII digest of
FX-174 RF DNA (The positions of the 495, 162 and 79 bp fragments are
indicated in the margin).
4
Fig. 3. EJfrct of cell density on GM-CSF secretion in primary renal cell
cultures. Group 1: Normal rcnal cells, sample 1840N; Group 2: Normal
renal cells, sample 1874N; Group 3: Renal carcinoma cells, sample 18751;
Group 4: Normal renal cells, sample 2001N. Symbols are: (U subconflu-
ent cultures; () confluent cultures. Secretion rate is expressed as
[ng/I0*6 cells/24 hr].
Third, conditioned media contained a substance that was recog-
nized in ELISA by monoclonal and polyclonal anti-human GM-
CSF antibodies. And fourth, the cells in the primary cultures
contained authentic human GM-CSF mRNA by the criterion of
RT-PCR.
Ninety-eight percent of human renal cell cultures (49 of 50)
secreted measurable amounts of GM-CSF. The mean GM-CSF
secretion in the 31 primary renal cultures assayed by ELISA
was 7.8 ng GM-CSF/106 cells/24 hr; 16 of these cultures produced
at least 6 ng GM-CSF/106 cells/24 hr, and 9 of those produced at
least 10 ng GM-CSF/106 cells/24 hr. One culture produced more
than 40 ng GM-CSF/106 cells/24 hr. By comparison, murine data
suggests that secretion of 24 to 48 ng GM-CSF/106 cells/24 hr (by
ELISA) would confer systemic, protective immunity to human
RCC [3]. No significant differences were observed in the present
study between mean rates of secretion in cultures derived from
malignant and normal renal cells. The amounts of GM-CSF
secreted by the individual cell cultures varied considerably, as
indicated by the SDS of the means, which ranged from approxi-
mately 50 to 115%. This variability was not correlated with the
patient's age, sex, pathological diagnosis, or the rate of secretion
in the paired sample.
The rate of GM-CSF secretion was independent of the age of
the culture over a two month interval spanning the second
through sixth passages. In addition, GM-CSF was also secreted by
each of two established renal cell lines. Together these results
demonstrate that the secretion of GM-CSF by primary cultures is
a long-term effect that is not induced by treatment with collage-
nase and is not due to fibroblasts, tumor infiltrating lymphocytes
or other contaminating cell types. This conclusion is also consis-
tent with the finding that GM-CSF was not secreted in significant
amounts by primary cultures derived from kidney tumors that
were not renal in origin, including a metastatic colon carcinoma
and a liposarcoma, but was secreted by the paired cultures derived
from adjacent, normal kidney tissue. If the methods used for
deriving primary renal cell cultures had favored the outgrowth of
other cell types present in the normal kidney, such as renal
fibroblasts or tumor infiltrating lymphocytes, these cells would
also have contaminated cultures similarly prepared from kidney
tumors that were not of renal origin.
Previous studies have shown that murine fibroblasts secrete
GM-CSF when cultured in the presence of fetal bovine serum
(FBS) and the cytokine lL-1 [12j. Thus, one potential explana-
tion for the finding that cultures of renal cells secrete GM-CSF in
medium supplemented with FBS, while other cell types do not,
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was that cultured renal cells constitutively secrete IL-la. How-
ever, more than 80% (9 of 11) of cultures secreting GM-CSF did
not produce detectable amounts of IL-i. GM-CSF was also
secreted by primary cultures of renal cells grown in serum-free
medium. Taken together, the observations that cells of non-renal
origin grown under the same conditions do not make GM-CSF,
that renal cell cultures do not make IL-I a, that renal cell cultures
make GM-CSF in serum-free medium, and that FBS contains no
proteins cross reactive with antibodies directed against 11 differ-
ent human cytokines argues strongly against the possibility that
GM-CSF secretion is induced by undefined cytokines in FBS.
The finding that cultured renal cells secrete GM-CSF raises the
question of whether or not GM-CSF is also produced by renal
cells in viva, as this may play a role in the spontaneous regressions
which occur occasionally in RCC 113, 14]. In this connection,
GM-CSF mRNA was not detected in the polyA+ RNA isolated
from any of nine samples of normal and cancerous kidneys
collected at surgery. Since 98% of the primary renal cultures
described in Tables 1 and 2 produced at least 0.2 ng GM-CSF/106
cells/24 hr (Tables 1 and 2), and the RT-PCR assay readily
detected GM-CSF mRNA in cells producing as little 0.14 ng
GM-CSF/106 cells/24 hr, we conclude that human renal cells in
vivo, unlike their dissociated and cultured counterparts, normally
do not produce detectable amounts of GM-CSF.
Two differences between the in vivo and in vitro environments
are implicated in the differential expression of GM-CSF by the
present investigation. The first difference is the number of cellular
contacts. The density of cells and resultant abundance of inter-
cellular contacts are much greater within undissociated kidney
tissue than in a subeonfluent culture. No GM-CSF expression was
detected in undissociated tissues. Additionally, the rates of GM-
CSF secretion in confluent cultures, which presumably approxi-
mate the in viva environment more closely than subconfluent
cultures, were as little as 1.2% of the rates in paired subconfluent
cultures. In contrast, GM-CSF expression was readily evident in
subconfluent cultures where intercellular contact was minimized.
The second difference implicated in the differential expression
of GM-CSF is the nature of cellular contacts. In viva, extracellular
matrix proteins and associated growth factors interact with each
other and with cells in tissue-specific combinations. This complex
matrix is absent in most culture systems, where either modified
polystyrene or a single protein provides the cellular substratum. In
contrast, Matrigel® provides a complex environment in which
many cell types have been shown to assume differentiation and
secretion characteristics similar to those observed in vivo. Accord-
ingly, the rates of GM-CSF secretion in suhconfluent cultures
grown on Matrigel® were less than 20% of the rates in paired
cultures grown on plastic. This reduction of renal cell GM-CSF
secretion by Matrigel® was specific, as the rates of GM-CSF
secretion were not significantly reduced in paired cultures grown
on several individual substrates also capable of interactions with
cell surface receptors, including mouse collagen IV and laminin
(which arc the two predominant constituents of Matrigel®),
human fibronectin, and the Arg-Gly-Asp (R-G-D) tripeptide. The
significantly reduced secretion of GM-CSF by cells cultured on
Matrigel®, which more closely resembles the in vivo environment,
is consistent with the interpretation that renal tissues do not
express GM-CSF in vivo. These results again imply that renal cell
GM-CSF expression is regulated by cellular contact, in this case
with specific components of the basement membrane.
Taken together, these results indicate for the first time that
GM-CSF is not expressed at detectable levels in human renal
tissue in viva, that stable expression is induced or derepressed
when kidney tissue is dissociated and cultured in vitro, and that the
rate of GM-CSF secretion is strongly affected by the cellular
environment. Little is currently known about the dose response
relationship between the levels of GM-CSF secreted by RCC cells
and their immuno-stimulatory activity in human patients. How-
ever, the rate of GM-CSF secretion in subeonfluent cultures
approached, and occasionally overlapped, the rate predicted from
animal models to have a therapeutic effect and that is produced by
the experimental human GM-CSF gene-modified RCC vaccine
that is now in clinical trials. These results suggest that it might be
feasible to define conditions that promote sustained, in viva
secretion of GM-CSF by non-transduced cells for use as RCC
vaccines. Further characterization of conditions that result in
optimal expression of GM-CSF will provide a better understand-
ing of the regulation of renal cell cytokine secretion and could
lead to novel means for immunotherapy of RCC.
Acknowledgments
Partial funding for this project was provided by a Program Development
Grant from the University of New Mexico Cancer Research and Treat-
ment Center. Preliminary accounts of portions of this work were presented
at the 1995 Annual Meeting of the American Urological Association (Las
Vegas, NV) and at the Fourth Internatiooal Conference on the Gene
Therapy of Cancer (San Diego, CA).
Reprint requests to fe/frey K Griffith, Ph.D., Department of Biochemistiy,
University of New Mexico School of Medicine, Albuquerque, New Mexico
87131, USA. E-mail: Griffith@unm.edu.
References
1. TEPPER RI, MULE JJ: Experimental and clinical studies of cytokine
gene-modified tumor cells. Hum Gene Ther 5:153—164, 1994
2. YAMABE T, DHIR G, COWAN EP, WOLF A, BERGEY GK, KRUMHOLZ
A, BARRY E, HOFFMAN PM, DHIB-JALBUT S: Cytokine gene expres-
sion in measles-infected adult human glial cells. J Neuroimmunol
49:171—179, 1994
3. BERNS AJM, CLIFr S, COHEN LK, DONEIIOWER RC, DRANOFF G,
HAUDA K, JAFFEE EM, LAZENBY Al, LEVITSKY HI, MARSHALL FF,
MULLIGAN RC, NELSON WG, OWEN AH, PARDOLL DM, PARRY G,
PARTIN AH, PIANTADOSI S, SIM0N5 JW, ZABORA JR: Phase I study of
non-replicating autologous tumor cell injections using cells prepared
with or without GM-CSF gene transduction in patients with metastatic
renal cell carcinoma. Hum Gene Ther 6:347—368, 1995
4. STEPHENS ND, GARCIA AM, GRIFFITH JK: Human renal cell produc-
tion of granulocyte-macrophage colony stimulating factor (GM-CSF)
in culture: Modulating factors- -ind concurrent production of other
cytokincs. (abstract) Cancer Gene Ther 2:3 19, 1995
5. GRIFFITH JK, SMITH AY, BARION SL, STEPHENS ND, NEIDHART JA,
PAUL RW: Production of granulocyte macrophage colony stimulating
factor (GM-CSF) in normal and cancerous human renal cells. (ab-
stract) f Urol 153:637a, 1995
6. Oosiwii F, RUITER J, WAKKA JC, HUISK[NS W, MEIJ D, JONAS U,
FIFUREN G-J, ZWARTENDIJK I, HOEDEMAEKER PH, WARNAAR SO:
Imniunohistochemical analysis of mouoclonal antibodies to reoal
antigens. Am f Patliol 123:301—309, 1986
7. KITAMIJRA I, Toio A, KUwAKI T, CHIBA S, MIYAZANO M, URADE A,
TAKAKU F: Identification and analysis of human erythropoictin recep-
tors in a factor-dependent cell line, TF-1. Blood 73:375—380, 1989
8. NOONAN KE, BECK C, HOLZMAYER TA, CHIN JE, WUNDER iS,
ANDRUI,IS JL, GAZOER AF, WIIIMAN CL, GRIFFITh BB, VONHOFF
DD, R0NIN50N IB: Quantitative analysis of MDRI (multi-drug resis-
tance) gene expression in human tumors by polymerase chain reac-
tion. Proc NatlAcad Sci USA 87:7160—7164, 1990
9. CANTREIL MA, ANDERSON D, CERRETTI DP, PRICE V, MCKJRKGHAN
1050 Stephens et al: GM-CSF secretion by human renal cells
K, TUSHINSKI RJ, MocHizuKi DY, LARSEN A, GRABSTEIN K, GILLIS 5,
COSMAN D: Cloning, sequencing and expression of a human granulo-
cyte/macrophage colony stimulating factor. Proc Nati Acad Sci USA
82:6250—6354, 1985
10. SHARMA 5, HUANG M, WG J, EcoNoMou iS, MCBRIDE WH, LEE P,
PAUL RW, TOLUZA E, DUBINE1T SM: Retroviral mediated IL-7 gene
transfer in human non-small cell lung cancer retards tumor cell
proliferation and enhances antitumor effector activities in vitro.
(abstract) Cancer Gene Ther 1:317, 1994
Ii. LUPTON SD, BRUNT0N LL, KALBERG VA, OVERELL RW: Dominant
positive and negative selection using a hygromycin phosphotrans-
ferase-thymidine kinase fusion gene. Mol Cell Biol 11:3374—3378, 1991
12. FALKENBURG JHF, HARRINGTON MA, DEPAUS, RA, WALSH WK,
DAUB R, LANDEGENT JE, BROXMEYER HE: Differential transcrip-
tional and post transcriptional regulation of gene expression of the
colony stimulating factors by interleukin-1 and fetal bovine serum in
murine fibroblasts. Blood 78:658—665, 1991
13. MONTIE JE, STEWART BH, STRAFFON RA, BANOWSKY LHW, HE-
WITT CB, MONTAGUE DK: The role of adjunctive nephrectomy in
patients with metastatic renal cell carcinoma. J Urol 117:272—275,
1977
14. OLIVER RTD, NETHERSELLM ABW, BO1TOMLEY JM: Unexplained
spontaneous regression and alpha-interferon treatment for metastatic
renal cell carcinoma. BrJ Urol 63:128—131, 1989
